Polyunsaturated Fatty Acids as Potential Treatments for COVID-19-Induced Anosmia

TL;DR

This paper reviews whether omega-3 fatty acids can help treat loss of smell caused by COVID-19, but finds inconsistent evidence and calls for more research.

Contribution

The paper highlights the need for rigorous, large-scale studies to assess the therapeutic potential of omega-3 PUFAs for olfactory dysfunction.

Findings

A placebo-controlled trial found no significant effect of omega-3 PUFA supplementation on olfactory recovery.

Existing research has limitations like small sample sizes and lack of placebo controls.

More studies are needed to explore the role of PUFAs in managing viral infections and sensory recovery.

Abstract

Some individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) experience anosmia, or loss of smell. Although the prevalence of anosmia has decreased with the emergence of the Omicron variant, it remains a significant concern. This review examines the potential role of polyunsaturated fatty acids (PUFAs), particularly omega-3 PUFAs, in treating COVID-19-induced anosmia by focusing on the underlying mechanisms of the condition. Omega-3 PUFAs are known for their anti-inflammatory, neuroprotective, and neurotransmission-enhancing properties, which could potentially aid in olfactory recovery. However, study findings are inconsistent. For instance, a placebo-controlled randomized clinical trial found no significant effect of omega-3 PUFA supplementation on olfactory recovery in patients with COVID-19-induced anosmia. These mixed results highlight the limitations of existing research, including small sample sizes, lack of placebo controls, short follow-up periods, and combined treatments. Therefore, more rigorous, large-scale studies are urgently needed to definitively assess the therapeutic potential of omega-3 PUFAs for olfactory dysfunction. Further research is also crucial to explore the broader role of PUFAs in managing viral infections and promoting sensory recovery.

Figures